IL312859A - פורמולציות הניתנות להזרקה ולשאיפה - Google Patents
פורמולציות הניתנות להזרקה ולשאיפהInfo
- Publication number
- IL312859A IL312859A IL312859A IL31285924A IL312859A IL 312859 A IL312859 A IL 312859A IL 312859 A IL312859 A IL 312859A IL 31285924 A IL31285924 A IL 31285924A IL 312859 A IL312859 A IL 312859A
- Authority
- IL
- Israel
- Prior art keywords
- formulation
- dimethyltryptamine
- salt
- compound
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW110143066A TWI891942B (zh) | 2020-12-01 | 2021-11-18 | 氘化化合物 |
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GBGB2119021.0A GB202119021D0 (en) | 2021-11-18 | 2021-12-24 | Injectable and inhalable formulations |
| US202217574424A | 2022-01-12 | 2022-01-12 | |
| EP2022055324 | 2022-03-02 | ||
| PCT/EP2022/082486 WO2023089132A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312859A true IL312859A (he) | 2024-07-01 |
Family
ID=84440034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312859A IL312859A (he) | 2021-11-18 | 2022-11-18 | פורמולציות הניתנות להזרקה ולשאיפה |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4433049A1 (he) |
| JP (1) | JP2024540527A (he) |
| KR (1) | KR20240110836A (he) |
| AU (1) | AU2022393234A1 (he) |
| CA (1) | CA3238583A1 (he) |
| CL (1) | CL2024001452A1 (he) |
| CO (1) | CO2024007518A2 (he) |
| IL (1) | IL312859A (he) |
| MX (1) | MX2024005955A (he) |
| WO (1) | WO2023089132A1 (he) |
| ZA (1) | ZA202403906B (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0715579A2 (pt) * | 2006-10-19 | 2015-05-26 | Auspex Pharmaceuticals Inc | "composto, composição farmacêutica e uso de um composto" |
| EA202192318A1 (ru) * | 2019-02-22 | 2021-12-21 | Гх Рисерч Айрленд Лимитед | 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP4180037A1 (en) | 2019-11-07 | 2023-05-17 | Small Pharma Ltd | Method of synthesis |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| IL298129B2 (he) * | 2020-08-28 | 2024-11-01 | Cybin Uk Ltd | פורמולציה הניתנת להזרקה המכילה את מלח הפומאראט של דימתילטריפטאמין או דימתילטריפטאמין המכיל דאוטריום |
| EP4031529B1 (en) * | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
-
2022
- 2022-11-18 IL IL312859A patent/IL312859A/he unknown
- 2022-11-18 MX MX2024005955A patent/MX2024005955A/es unknown
- 2022-11-18 JP JP2024529536A patent/JP2024540527A/ja active Pending
- 2022-11-18 AU AU2022393234A patent/AU2022393234A1/en active Pending
- 2022-11-18 WO PCT/EP2022/082486 patent/WO2023089132A1/en not_active Ceased
- 2022-11-18 CA CA3238583A patent/CA3238583A1/en active Pending
- 2022-11-18 KR KR1020247020007A patent/KR20240110836A/ko active Pending
- 2022-11-18 EP EP22818741.5A patent/EP4433049A1/en active Pending
-
2024
- 2024-05-15 CL CL2024001452A patent/CL2024001452A1/es unknown
- 2024-05-20 ZA ZA2024/03906A patent/ZA202403906B/en unknown
- 2024-06-14 CO CONC2024/0007518A patent/CO2024007518A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024007518A2 (es) | 2024-07-29 |
| EP4433049A1 (en) | 2024-09-25 |
| CL2024001452A1 (es) | 2024-09-27 |
| MX2024005955A (es) | 2024-06-11 |
| WO2023089132A1 (en) | 2023-05-25 |
| AU2022393234A1 (en) | 2024-06-06 |
| KR20240110836A (ko) | 2024-07-16 |
| JP2024540527A (ja) | 2024-10-31 |
| CA3238583A1 (en) | 2023-05-25 |
| ZA202403906B (en) | 2025-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2384384T3 (es) | Formulaciones inhalables para tratar la hipertensión pulmonar y procedimientos de uso de las mismas | |
| KR100962059B1 (ko) | 항콜린 유효 화합물과 β-유사체를 기본으로 하는 신규한약제학적 조성물 | |
| KR20080005601A (ko) | Ｐｄｅ４ 억제제 로플루밀라스트와 테트라히드로비오프테린유도체의 조합 | |
| JPWO1999002158A1 (ja) | ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物 | |
| IL298129B2 (he) | פורמולציה הניתנת להזרקה המכילה את מלח הפומאראט של דימתילטריפטאמין או דימתילטריפטאמין המכיל דאוטריום | |
| KR102020939B1 (ko) | 암 치료 시스템, 방법 및 제형 | |
| JPH11263728A (ja) | 性機能不全のための治療剤 | |
| EA002174B1 (ru) | Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин | |
| EA013351B1 (ru) | Фармацевтические препараты, содержащие бета-агонист длительного действия, для введения путем распыления | |
| JP2023540149A (ja) | 抗ウイルス化合物の製剤 | |
| KR20200018485A (ko) | 우울 장애들의 치료 | |
| US8450356B2 (en) | Pharmaceutical composition | |
| JP2021506897A (ja) | フドステインのエアロゾル吸入用溶液製剤及びその製造方法 | |
| KR20240165490A (ko) | 비강내 에피네프린 제제 및 질환의 치료 방법 | |
| EP1782816B1 (en) | Water-based medicinal composition containing azithromycin and method of preparing the same | |
| JP2024540527A5 (he) | ||
| WO2013108180A1 (en) | Aqueous paracetamol composition for injection | |
| CN1617716A (zh) | 杂环衍生物与使用方法 | |
| US10555917B1 (en) | Methods of treating a neurological or psychiatric disorder | |
| JP5563528B2 (ja) | ニコチン酸アミドを含有するゲムシタビン凍結乾燥製剤 | |
| TW201002368A (en) | Unit dose formulations of ketorolac for intranasal administration | |
| TW202114717A (zh) | 含有對硼苯基丙胺酸之注射液劑 | |
| CN1871011A (zh) | Bh4在治疗呼吸系统疾病中的用途 | |
| CN113546081A (zh) | 一种含有度洛西丁的药物组合物及其应用 | |
| JP2654518B2 (ja) | 肝細胞増殖促進剤 |